entertainment -WSS

entertainment

author：hotspot 2025-09-29 10:34:41 - browse：1

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Wearables generate powerful data but its not useful to doctors, yet

entertainment

WSS

Data integrity in scientific journals requires "effort" by publishers, institutions

First Opinion Podcast: Long Covid needs a new approach

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Venture capitalist Bob Kocher on the state of digital health

Wearables generate powerful data but its not useful to doctors, yet

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

STAT Readout Newsletter: Today's biggest biotech updates

How to save PrEP access — and even expand it

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Malaria cases in Florida and Texas: Here’s what you need to know

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cytokinetics CEO stresses company can launch heart drug on its own

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why health workers in Gaza are injured or die at high rates

leisure time

It's time to retire 'poor historian' from clinicians' vocabularies

Eli Lilly expects to double planned employment in Boston center

Will Ozempic

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

FDA gives detailed accounting of AI

2023 STAT Wunderkinds: get to know the winners

Wikipedia

entertainment

hotspot

leisure time